细胞免疫治疗在复发/难治经典型霍奇金淋巴瘤中的研究进展OA
Progress in cellular immunotherapy for relapsed/refractory classical Hodgkin lymphoma
经典型霍奇金淋巴瘤(classical Hodgkin lymphoma,cHL)经规范一线治疗大多可获得长期缓解,但仍有部分患者出现原发难治或复发.以嵌合抗原受体T细胞(chimeric antigen receptor T cells,CAR-T)、EB病毒特异性T细胞(Epstein-Barr virus-specific T cells,EBVST)及自然杀伤(natural killer,NK)细胞为基础的细胞免疫治疗,为复发/难治经典型霍奇金淋巴瘤(relapsed/refractory classical Hodgkin lymphoma,R/R cHL)提供了新的治疗思路.现有证据主要来自Ⅰ/Ⅱ期单臂、小样本研究,其中CD30 CAR-T的临床数据相对集中,可实现较高缓解率,但单次输注后的缓解持久性有限;EBVST安全性较好,主要适用于EBV阳性患者,但其在R/R cHL中的直接证据尚不足;AFM13预复合NK细胞具备异体来源、可预制备和急性免疫毒性较低等特点,但长期疾病控制效果仍需改善.本文围绕R/R cHL的免疫逃逸基础与细胞免疫治疗靶点,系统评述上述三类治疗策略的疗效证据,并总结其优化策略及安全管理要点,旨在为临床治疗选择和后续研究设计提供参考.
Most patients with classical Hodgkin lymphoma(cHL)achieve durable remission after standard first-line therapy,but some patients develop primary refractory disease or relapse.Cellular immunotherapies based on chimeric antigen receptor T cells(CAR-T),Epstein-Barr virus-specific T cells(EBVST),and natural killer(NK)cells provide new therapeutic approaches for relapsed/refractory classical Hodgkin lymphoma(R/R cHL).Current evidence is derived mainly from phase Ⅰ and Ⅱ single-arm studies with small sample sizes.Clinical data are most extensive for CD30 CAR-T therapy,which can induce high response rates,although the durability of response after a single infusion remains limited.EBVST therapy has a favorable safety profile and is mainly applicable to patients with EBV-positive disease,but direct evidence in R/R Chl remains limited.AFM13-precomplexed NK cells have potential advantages including allogeneic sourcing,off-the-shelf availability,and relatively low acute immune toxicity,although long-term disease control remains limited.This review focuses on the biological basis of immune evasion and targets of cellular immunotherapy in R/R Chl,systematically evaluates the efficacy evidence for these three strategies,and summarizes optimization strategies and key aspects of safety management,with the aim of informing clinical treatment selection and future study design.
杨玉琳;肖毅
430030 武汉 华中科技大学同济医学院附属同济医院血液内科430030 武汉 华中科技大学同济医学院附属同济医院血液内科
医药卫生
经典型霍奇金淋巴瘤复发/难治细胞免疫治疗嵌合抗原受体T细胞EB病毒特异性T细胞自然杀伤细胞
Classical Hodgkin lymphomaRelapsed/refractoryCellular immunotherapyChimeric antigen receptor T cellsEpstein-Barr virus-specific T cellsNatural killer cells
《中国癌症防治杂志》 2026 (4)
479-489,11
国家自然科学基金项目(823701968187344482070213)
评论